©© 2008 American College of Clinical Pharmacology, Inc.
The Journal of Clinical Pharmacology
, 10.1177/0091270008320318
Pharmacokinetics and Pharmacodynamics of Pegfilgrastim in Subjects With Various Degrees of Renal Function
Bing-Bing Yang 1*,
Anna Kido 1,
Margaret Salfi 1,
Suzanne Swan 2,
and
John T. Sullivan 1
1 Amgen Inc
2 DaVita Clinical Research and Hennepin County Med Center
* To whom correspondence should be addressed. E-mail: byang{at}amgen.com.
 |
Abstract |
|---|
A phase I study was conducted to evaluate the effects of renal function on the pharmacokinetics and pharmacodynamics (absolute neutrophil count [ANC]) of pegfilgrastim in nonneutropenic subjects. Thirty subjects categorized into 5 renal function groups (normal, mildly impaired, moderately impaired, severely impaired, and end-stage renal disease) received 1 subcutaneous injection of pegfilgrastim at 6 mg. The ANC profiles after pegfilgrastim administration were similar across different renal function groups. No discernable correlation between pharmacokinetic parameter values and degree of renal impairment was observed; the mean values ranged from 147 to 201 ng/mL for Cmax and from 7469 to 8513 ngxh/mL for AUC. Results suggest that the kidney has no important role in the elimination of pegfilgrastim. Therefore, no dosage adjustment for renal impairment is indicated for pegfilgrastim.
